These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 26426431

  • 1. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, Kim YA, Kim TM, Heo DS, Kim CW, Jeon YK.
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [Abstract] [Full Text] [Related]

  • 2. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
    Mitteldorf C, Berisha A, Pfaltz MC, Broekaert SMC, Schön MP, Kerl K, Kempf W.
    Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M, Huang X, Ye X, Qian W.
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A, Ochiai A.
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [Abstract] [Full Text] [Related]

  • 8. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M, Pirel M, Costes-Martineau V, Bauchet L, Fabbro M, Tourneret A, De Oliveira L, Durand L, Roger P, Gonzalez S, Cacheux V, Rigau V, Szablewski V.
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [Abstract] [Full Text] [Related]

  • 9. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y, Furuta T, Ohshima K, Komaki S, Miyoshi J, Morioka M, Abe H, Nozawa T, Fujii Y, Takahashi H, Kakita A.
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E, Kato S, Shimada K, Tanaka T, Suzuki Y, Satou A, Kohno K, Sakakibara A, Yamamura T, Nakamura M, Miyahara R, Goto H, Nakamura S, Hirooka Y.
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY, Lin MW, Chang YL, Wu CT, Yang PC.
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [Abstract] [Full Text] [Related]

  • 14. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY, Xu XL, Rao HL, Chen J, Lai RC, Huang HQ, Jiang WQ, Lin TY, Xia ZJ, Cai QQ.
    Chin J Cancer; 2017 Dec 16; 36(1):94. PubMed ID: 29246182
    [Abstract] [Full Text] [Related]

  • 15. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ.
    Oncotarget; 2016 Sep 13; 7(37):59976-59986. PubMed ID: 27527850
    [Abstract] [Full Text] [Related]

  • 16. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
    Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y.
    Medicine (Baltimore); 2017 Apr 13; 96(15):e6398. PubMed ID: 28403071
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.